Brief: Novo Says Ozempic Cuts Risk Of Major Cardiovascular Events
29/09/2026 15:13
BRIEF-Novo Says Ozempic Cuts Risk Of Major Cardiovascular Events Sept 29 (Reuters) - Novo Nordisk A/S NOVOb.CO:
NOVO'S OZEMPIC (SEMAGLUTIDE) 2 MG ASSOCIATED WITH LOWER RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (DEATH, HEART ATTACK, AND STROKE) IN ADULTS WITH TYPE 2 DIABETES COMPARED TO SWITCHING TO MOUNJARO (TIRZEPATIDE), IN REAL-WORLD ANALYSIS AT EASD
SEMAGLUTIDE 2 MG DOSE ESCALATION LINKED TO 6% LOWER RISK OF MAJOR CARDIOVASCULAR EVENTS
OZEMPIC 2 MG ASSOCIATED WITH LOWER RISK OF MAJOR CARDIOVASCULAR EVENTS VERSUS MOUNJARO
Source text: ID:nPnSjH8ka
Further company coverage: [NOVOb.CO]
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Novo Nordisk A/S
See all newsIndia's Torrent Pharma's profit slips as R&D costs outweigh domestic demand
Dr Reddy's rolls out new generic Ozempic brands amid Obeda supply disruption
GLP-1 boom in China, India, Brazil could create $22 bln market by 2035, J.P. Morgan says
Dr Reddy's rolls out new generic Ozempic brands amid Obeda supply disruption
Weight-loss drugs fuel protein boom, but with more consumer scrutiny